13F-HR: Johnson & Johnson's Q1 2024 13F Filing Reveals Significant Biotech Investments

Johnson & Johnson's Q1 2024 13F filing reveals a $4.4 billion portfolio with substantial holdings in biotech and pharmaceutical companies.

Summary

• Johnson & Johnson filed its Form 13F for the quarter ended March 31, 2024.
• The filing reveals the company's holdings, with a total value of $4,413,028,814.
• The filing includes holdings from Johnson & Johnson and Johnson & Johnson Innovation JJDC, Inc.
• The company holds positions in various biotech and pharmaceutical companies, including CVRx, Inc., Fate Therapeutics, Inc., and Legend Biotech Corporation.
• Kenvue Inc. is the largest holding, valued at $3,912,792,143 representing 182,329,550 shares.

Sentiment

Score: 7

Explanation: The document is a standard 13F filing, which is inherently neutral. However, the size and composition of the portfolio suggest a positive outlook on the biotech and pharmaceutical industries.

Positives

• The filing provides insight into Johnson & Johnson's investment strategy in the biotech and pharmaceutical sectors.
• The large investment in Kenvue Inc. indicates a strong belief in the company's potential.
• The diverse portfolio suggests a strategy of spreading risk across multiple companies and therapeutic areas.

Risks

• The value of the holdings is subject to market fluctuations and the performance of the individual companies.
• Investments in biotech companies carry inherent risks related to drug development, regulatory approvals, and clinical trial outcomes.

Future Outlook

The document does not contain specific forward-looking statements, but the investment portfolio reflects Johnson & Johnson's strategic interests in the healthcare sector.

Industry Context

Johnson & Johnson's investment activity reflects the ongoing interest and capital flow into the biotech and pharmaceutical industries, particularly in companies developing innovative therapies and technologies.

Comparison to Industry Standards

• Comparing Johnson & Johnson's investment portfolio to other major pharmaceutical companies' 13F filings could reveal trends in investment focus and risk appetite.
• Benchmarking the performance of Johnson & Johnson's holdings against industry indices like the Nasdaq Biotechnology Index (NBI) can provide insights into the effectiveness of their investment strategy.
• Comparing the size of Johnson & Johnson's investments in specific companies to those of other institutional investors can indicate market sentiment and potential for future growth.

Stakeholder Impact

• The investment activity can impact the share prices of the companies held in the portfolio.
• The investments support the development of new therapies and technologies, potentially benefiting patients and healthcare providers.
• The filing provides transparency to shareholders regarding Johnson & Johnson's investment strategy.

Key Dates